Multimodal Imaging Based on Pathological and Genomic Characteristics

Overview

Mitochondrial DNA mutations in normal gastric tissue, early gastric cancer and advanced gastric cancer were identified by single cell sequencing, and the origin of gastric stem cells was traced and new molecular markers were found. At the same time, organize industry-university-research-medical inspection joint research, aiming at the advanced layout of new structural and functional imaging technologies, combined with some new imaging technologies, such as holography, fluorescence, etc., to explore and develop a new composite endoscopic imaging technology that is advanced, original and suitable for China's national conditions, in order to develop a prototype of multimodal structural and functional imaging digestive endoscope without contrast agent.

Full Title of Study: “A New Multimodal Imaging Technique Based on Pathological and Genomic Characteristics of Gastrointestinal Mucosa”

Study Type

• Study Type: Observational
• Study Design
  • Time Perspective: Prospective
• Study Primary Completion Date: June 1, 2022

Detailed Description

In this study, on the basis of previous work, aiming at the visualization of key molecular functions of gastric cancer, a full-chain digestive endoscopic diagnosis system was constructed by using cross-scale medical imaging technology. Mitochondrial DNA mutations in normal gastric tissue, early gastric cancer and advanced gastric cancer were identified by single cell sequencing, and the origin of gastric stem cells was traced and new molecular markers were found. The tissue characteristics are analyzed by the full spectrum imaging device, and the location, distribution and aggregation of key molecules on the cell membrane are observed by the high resolution imaging device, so as to develop an imaging probe with high labeling efficiency and biosafety, and to explore its clinical application to realize the information fusion of structural and functional imaging in the evolution and diagnosis and treatment of gastrointestinal tumors. The structural heterogeneity and molecular heterogeneity of gastrointestinal tumors are clarified from the macro-micro levels, and the full-scale imaging system with the most comprehensive visualization and resolution ability is established from multi-information dimensions and multi-imaging scales.

Interventions

• Other: Patients diagnosed as gastrointestinal mucosal lesions
  • Patients diagnosed as gastritis, gastric cancer, intestinal polyps and colorectal cancer

Arms, Groups and Cohorts

• Study Group
  • Study on the genomic and molecular pathological characteristics of gastrointestinal mucosal lesions
• Control Group
  • Study on the genomic and molecular pathological characteristics of normal gastrointestinal mucosa

Clinical Trial Outcome Measures

Primary Measures

• Single cell sequencing and identification of mitochondrial DNA variation in gastrointestinal lesions
  • Time Frame: 1 month
  • Single cell sequencing and identification of mitochondrial DNA mutations in gastrointestinal lesions were carried out to trace the clonal origin of cells and look for molecular markers
• To explore the multimodal imaging technique for the diagnosis of gastrointestinal mucosal lesions
  • Time Frame: 1 month
  • The tissue characteristics are analyzed by the full spectrum imaging device, the location, distribution and aggregation of key molecules on the cell membrane are observed by the high resolution imaging device, the imaging probe with high labeling efficiency and biosafety is developed, and the clinical application is discussed. in order to realize the information fusion of structural and functional imaging in the process of gastrointestinal tumor evolution and diagnosis and treatment.

Participating in This Clinical Trial

Inclusion Criteria

1. Diagnosis or suspected diagnosis of one of the following common digestive mucosal diseases: gastritis, gastric cancer, colorectal polyps, bowel cancer 2. Written informed consent Exclusion Criteria:

1. Patients with cardiovascular and cerebrovascular diseases, or patients with severe impairment of liver, kidney and hematopoietic system 2. Mental patients 3. Hemorrhagic diseases 4. Platelet count < 50 × 10 ^ 9 / L 5. Allergic constitution 6. unable to tolerate or cooperate with endoscopy 7. Patients with serious complications, such as intestinal obstruction, intestinal perforation, toxic colonic dilatation, colorectal cancer, etc. 8. Pregnant or lactating women

Gender Eligibility: All

Minimum Age: 18 Years

Maximum Age: 80 Years

Are Healthy Volunteers Accepted: Accepts Healthy Volunteers

Investigator Details

• Lead Sponsor
  • Affiliated Hospital to Academy of Military Medical Sciences
• Provider of Information About this Clinical Study
  • Sponsor
• Overall Official(s)
  • Yan Liu, MD, Principal Investigator, Beijing 302 Hospital
• Overall Contact(s)
  • Yan Liu, MD, +8613911798288, 13911798288@163.com